18:02 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cocktails of AAV vectors encoding anti-HIV bNAbs to treat the infection

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Non-human primate studies suggest cocktails of viral vectors encoding broadly neutralizing antibodies (bNAbs) against multiple HIV antigens could help treat HIV. The antibodies consist of variable regions of previously...
19:11 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

gp120-binding bNAbs for HIV

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Cell culture studies suggest broadly neutralizing antibodies (bNAbs) that bind two adjacent HIV gp120 monomers in HIV env could help prevent and treat HIV-1 infection. The bNAbs were generated...
17:38 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

ViiV's fostemsavir maintains virologic suppression at week 48 in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said fostemsavir plus optimized background therapy maintained virologic suppression of less than 40 copies/mL from week 24 to 48 in 54% of heavily treatment-experienced patients with HIV-1 infection in the...
17:57 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
15:54 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection...
18:19 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Patient sample and cell culture studies identified three broadly neutralizing antibodies (bNAbs) against HIV gp120 that could help treat the infection. Screening of neutralizing antibodies against HIV gp120 isolated from a patient with...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a neutralizing antibody against HIV gp120 that could help treat HIV/AIDS. Screening of peripheral blood B cells from a patient followed by testing of...
04:48 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ViiV's HIV candidate fostemsavir meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) (formerly BMS-663068) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir...
23:27 , Oct 27, 2017 |  BC Extra  |  Clinical News

ViiV's HIV candidate meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to...
00:01 , Sep 21, 2017 |  BC Extra  |  Preclinical News

NIAID, Sanofi develop trispecific bNAb for HIV

In a paper published in Science, researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and Sanofi (Euronext:SAN; NYSE:SNY) identified a trispecific broadly neutralizing antibody (bNAb) which conferred 100% protection against simian HIV...